General

 CAS Key Laboratory of Mental Health, 

Institute of Psychology, Chinese Academy of Sciences (CAS)

16 Lincui Road, Chaoyang District, Beijing, 100101,China

Tel: (86-10)64879520

​Email: zhangxy@psych.ac.cn


Research Areas

Clinical Psychological Therapy and Counseling

Cognitive Function Research in Mental Disorders

Relationship Between Smoking and Mental Disorders

Free Radical Metabolism in Mental Disorders

Immune Function in Mental Disorders

Genetic Research in Mental Disorders

Neurotrophic Factor Research in Mental Disorders

Neuroelectrophysiological Research in Mental Disorders

Magnetic Resonance Imaging Research in Mental Disorders

Clinical Psychopharmacology Research in Mental Disorders: Clinical Efficacy and Three Major Side Effects of Drugs (Tardive Dyskinesia, Diabetes, and Obesity)

Education

Ph.D.  Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,

           Beijing, CHINA.   Sep 1995-July 1998

M.S.   Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,

            Beijing, CHINA.   Sep 1992-July 1995

M.D.    Anhui Medical University, HeFei, Anhui, CHINA.   Sep 1984- July 1989


Experience

   
Work Experience

March 2018- present   Professor, Institute of Psychology

                                    Chinese Academy of Sciences, Beijing, China      

July 2014- Feb 2018 Associate Professor, Attending Psychiatrist

                                    Department of Psychiatry and Behavioral Sciences,

                                    The University of Texas Health Science Center at Houston, Texas, USA

July 2009- July 2014  Associate Professor, Department of Psychiatry and Behavioral Sciences,

                                      Baylor College of Medicine, Houston, Texas, USA

July 2006-June 2009  Assistant Professor, Department of Psychiatry and Behavioral Sciences,

                                      Baylor College of Medicine

July 2003-June 2006   Associate Research Scientist, Department of Psychiatry,

                                      Yale University School of Medicine, Connecticut, USA

Aug 2000-June 2003   Postdoctoral Fellow, Department of Psychiatry,

                                       Yale University School of Medicine, Connecticut, USA

Aug 1999-July 2000    Postdoctoral Fellow, Center for Molecular and Behavioral Neuroscience

                                       Rutgers University, New Jersey, USA  

Aug 1998-July 1999    Research Fellow, Institute of Mental Health,

                                        Peking University School of Medicine, Beijing, China  

Aug 1994-July 1998    Attending Psychiatrist, Beijing Hui-Long-Guan Psychiatric Hospital,   

                                        Beijing, China

Aug 1989-July 1994   Resident in Psychiatry, Beijing Hui-Long-Guan Psychiatric Hospital,  

                                        Beijing, China 

Publications

Papers

1. Li X,Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho RY, Kosten TR, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: A double-blind, randomized, sham-controlled study. BMC Medicine 2024 (in print) (IF=9.3)

2. Wang DM, Chen DC, Xiu MH, Wang L, Kosten TR, Zhang XY. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology 2024 Apr;49(5):893-902(IF=7.6)

3.Qu M, Yang K, Cao Y, Wang X, Tan S, Xiu M, Zhang X. Symptoms of Anxiety and Depression Among Adolescents Before vs During COVID-19-Related School Closures in China.  JAMA Network Open 2022; 5(11):e2241752.

4. Zhang XY, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X,   Wu F, Soares JC, Cao B, Wang L, Chen H. Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Molecular Psychiatry  2020;25(12):3220-3230  (IF=11)

5. Cao B, Cho RY, Chen D, Xiu M, Wang L, Soares JC, Zhang XY. Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity. Molecular Psychiatry 2020; 25(4):906-913 (IF=11)

6.  Xiu MH, Li Z, Curbo ME, Wu HE, Chen DC, Chen S, Tong YS, Tan SP, Zhang XY. Interrelationships between BDNF, superoxide dismutase and cognitive impairment in first episode drug-naive patients with schizophrenia. Schizophrenia Bulletin 2020; 46(6):1498-1510

7. Qu M, Wang J, Chen DC, Chen S, Xiu MH, Zhang XY. Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia. Free Radical and Biological Medicine 2020;160:887-893

 8. Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, Zhou H, Xu H, Tian Y, Dai Q, Wu HE, Chang C, Wang L, Kosten TR, Zhang XY. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacology 2020; 45(8):1362-1368

9. Xiu MHGuan HYZhao JMWang KQPan YFSu XRWang YHGuo JMJiang L, Liu HY, Sun SGWu HR,  Liu XWYu HJWei BCLi XPTrinh TTan SP, Zhang XY. Cognitive Enhancing Effect of High-Frequency Neuronavigated rTMS in Chronic Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind Controlled32-Week Follow-up Study. Schizophrenia Bulletin 2020; 46(5):1219-1230

 10. Yang M, Gao S, Zhang X. Cognitive deficits and white matter abnormalities in never- treated first-episode schizophrenia. Translational Psychiatry 2020; 10(1):368.